1. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study). (27th April 2018) Authors: Lambert-Niclot, S; Grude, M; Chaix, M L; Charpentier, C; Reigadas, S; Le Guillou-Guillemette, H; Rodallec, A; Amiel, C; Maillard, A; Dufayard, J; Mourez, T; Mirand, A; Guinard, J; Montes, B; Vallet, S; Marcelin, A G; Descamps, D; Flandre, P; Delaugerre, C; Morand-Joubert, L Journal: Journal of antimicrobial chemotherapy Issue: Volume 73:Number 8(2018) Page Start: 2147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. (4th June 2018) Authors: Nguyen, T; Fofana, D B; Lê, M P; Charpentier, C; Peytavin, G; Wirden, M; Lambert-Niclot, S; Desire, N; Grude, M; Morand-Joubert, L; Flandre, P; Katlama, C; Descamps, D; Calvez, V; Todesco, E; Marcelin, A G Journal: Journal of antimicrobial chemotherapy Issue: Volume 73:Number 9(2018) Page Start: 2485 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗